Tony Cates joins Cycle Group Holdings Board of Directors

By |2022-11-30T11:31:47+00:00October 6th, 2021|News, Nityr|

Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)

By |2022-11-30T11:32:04+00:00September 28th, 2021|News, Nityr|

Cycle Pharmaceuticals Launches Cycle Vita™, a dedicated support platform for rare disease patients

By |2022-11-30T11:32:18+00:00September 10th, 2021|News, Nityr|

Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors

By |2022-11-30T11:33:22+00:00April 29th, 2021|News, Nityr|

NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand

By |2022-11-30T11:33:41+00:00March 15th, 2021|News, Nityr|

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel

By |2021-05-17T18:52:30+01:00October 19th, 2020|News, Nityr|

Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)

By |2021-05-17T18:52:31+01:00August 5th, 2020|News, Nityr|

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia

By |2021-05-17T18:52:31+01:00May 13th, 2020|News, Nityr|

Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology

By |2021-05-17T18:52:31+01:00May 5th, 2020|News, Nityr|

Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

By |2021-05-17T18:52:31+01:00December 18th, 2019|News, Nityr|
Go to Top